Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2018 Sep 20

PMID 30229387

Citations 14

Authors

Laura J Tucker

Weiyu Ye

Laura C Coates

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Psoriatic arthritis (PsA) is a chronic inflammatory spondyloarthritis that can cause progressive joint damage and irreversible disability. Advances in modern therapies, now mean a target of remission is an achievable goal in PsA. There is strong and consistent evidence that a treat-to-target (T2T) approach to PsA management results in better patient outcomes; however, the practicalities of incorporating this strategy into routine clinical practice remain a challenge. The heterogeneous nature of this condition and the need for validated outcome measures have to-date hampered consensus on a definition of remission. This review aims to summarise the current T2T research landscape in PsA and highlight potential roles for biomarkers and imaging advances in revolutionising the T2T concept.

Recent Findings: There is a growing body of evidence to support the implementation of a T2T strategy, using a pre-defined target in PsA management, with significant benefits in disease outcome, physical function and quality of life. Whilst remission is the ultimately goal for PsA patients and their clinicians, further comparative studies of different treatment targets are needed to establish a widely acceptable definition of remission.

Citing Articles

Serum Interleukin (IL)-6, Lipid Profile, and Association With Disease Severity in Patients With Psoriasis: A Cross-Sectional Study.

Sahoo S, Das K, Panda B, Pandey M, Acharya M, Meher P Cureus. 2024; 16(9):e69599.

PMID: 39429270 PMC: 11486630. DOI: 10.7759/cureus.69599.

Management of psoriatic arthritis: a consensus opinion by expert rheumatologists.

DAngelo S, Atzeni F, Benucci M, Bianchi G, Cantini F, Caporali R Front Med (Lausanne). 2023; 10:1327931.

PMID: 38098852 PMC: 10720668. DOI: 10.3389/fmed.2023.1327931.

A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).

Liote F, Constantin A, Dahan E, Quiniou J, Frazier A, Sibilia J Rheumatology (Oxford). 2023; 63(2):516-524.

PMID: 37261843 PMC: 10836978. DOI: 10.1093/rheumatology/kead262.

A Joint Consensus of Rheumatologists and Dermatologists on Early Detection and Effective Management of Psoriatic Arthritis: India's Perspective.

Chatterjee M, Nayak C, De A, Rajadhyaksha S, Singh G, Kumar P Indian J Dermatol. 2022; 67(4):479.

PMID: 36578740 PMC: 9792027. DOI: 10.4103/ijd.ijd_939_20.

Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence.

Coates L, de Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie A Rheumatol Ther. 2022; 9(3):803-821.

PMID: 35412298 PMC: 9127027. DOI: 10.1007/s40744-022-00443-y.

References

Coates L, Helliwell P . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010; 62(7):965-9. DOI: 10.1002/acr.20155. View

Smolen J, Schols M, Braun J, Dougados M, FitzGerald O, Gladman D . Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017; 77(1):3-17. PMC: 5754738. DOI: 10.1136/annrheumdis-2017-211734. View

van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A . 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017; 76(6):978-991. DOI: 10.1136/annrheumdis-2016-210770. View

Brown A, Conaghan P, Karim Z, Quinn M, Ikeda K, Peterfy C . An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008; 58(10):2958-67. DOI: 10.1002/art.23945. View

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Dale J, Stirling A, Zhang R, Purves D, Foley J, Sambrook M . Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Ann Rheum Dis. 2016; 75(6):1043-50. DOI: 10.1136/annrheumdis-2015-208941. View

Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman D . Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2014; 67(2):264-72. DOI: 10.1002/acr.22401. View

Ortega C, Fernandez-A S, Carrillo J, Romero P, Molina I, Moreno J . IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009; 86(2):435-43. DOI: 10.1189/JLB.0109046. View

van Eijk I, Nielen M, van der Horst-Bruinsma I, Tijhuis G, Boers M, Dijkmans B . Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford). 2011; 51(4):686-94. PMC: 3306166. DOI: 10.1093/rheumatology/ker355. View

10.

Coates L, Fransen J, Helliwell P . Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2009; 69(1):48-53. DOI: 10.1136/ard.2008.102053. View

11.

Saleem B, Brown A, Quinn M, Karim Z, Hensor E, Conaghan P . Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. Ann Rheum Dis. 2012; 71(8):1316-21. DOI: 10.1136/annrheumdis-2011-200548. View

12.

Fransen J, Moens H, Speyer I, Van Riel P . Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005; 64(9):1294-8. PMC: 1755664. DOI: 10.1136/ard.2004.030924. View

13.

Miedany Y, El Gaafary M, Youssef S, Ahmed I, Nasr A . Tailored approach to early psoriatic arthritis patients: clinical and ultrasonographic predictors for structural joint damage. Clin Rheumatol. 2014; 34(2):307-13. DOI: 10.1007/s10067-014-2630-2. View

14.

Villanova F, Di Meglio P, Nestle F . Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013; 72 Suppl 2:ii104-10. DOI: 10.1136/annrheumdis-2012-203037. View

15.

Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-62. DOI: 10.1016/s0140-6736(98)04311-6. View

16.

Greenberg J, Palmer J, Li Y, Herrera V, Tsang Y, Liao M . Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort. J Rheumatol. 2015; 43(1):88-96. DOI: 10.3899/jrheum.150540. View

17.

Vermeer M, Kievit W, Kuper H, Braakman-Jansen L, Bernelot Moens H, Zijlstra T . Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord. 2013; 14:350. PMC: 3884120. DOI: 10.1186/1471-2474-14-350. View

18.

Haavardsholm E, Aga A, Olsen I, Lillegraven S, Hammer H, Uhlig T . Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. BMJ. 2016; 354:i4205. PMC: 4986519. DOI: 10.1136/bmj.i4205. View

19.

Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A . Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006; 65(9):1175-83. PMC: 1798296. DOI: 10.1136/ard.2005.046367. View

20.

Cresswell L, Chandran V, Farewell V, Gladman D . Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis. 2010; 70(2):305-8. DOI: 10.1136/ard.2010.135087. View